Addex Therapeutics Ltd - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ADXN Nasdaq 2830 www.addextherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Addex Therapeutics Ltd

Addex Amends its at the Market Offering Agreement With H.C. Wainwright & Co. - Dec 10th, 2025 11:00 pm
Addex Therapeutics Ltd (ADXN) Q3 2025 Earnings Call Highlights: Strategic Advances Amidst ... - Dec 4th, 2025 4:06 pm
Addex Therapeutics Reports 2025 Third Quarter Financial Results and Provides Corporate Update - Dec 3rd, 2025 11:00 pm
Addex Therapeutics to Report 2025 Third Quarter Financial Results And Host Conference Call on December 4, 2025 - Nov 30th, 2025 11:00 pm
Addex Increases Issued Share Capital to Create Treasury Shares - Oct 29th, 2025 12:00 am
Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Highlights: Strategic Advances Amid ... - Oct 1st, 2025 3:01 pm
Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update - Sep 29th, 2025 11:00 pm
Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 - Sep 25th, 2025 11:00 pm
Addex Appoints Bank of New York Mellon as Depositary Bank - Sep 22nd, 2025 11:00 pm
European Market Insights: Addex Therapeutics Among 3 Promising Penny Stocks - Sep 15th, 2025 5:05 am
Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders - Jun 29th, 2025 11:00 pm
Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs - Jun 29th, 2025 11:00 pm
Addex Shareholders Approve All Resolutions at Annual General Meeting - Jun 24th, 2025 11:00 pm
Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update - Jun 18th, 2025 11:00 pm
Addex Therapeutics to Release Q1 2025 Financial Results and Host Conference Call on June 19, 2025 - Jun 17th, 2025 11:00 pm
Addex GABAB PAM Candidate Demonstrates Robust Anti-Tussive Activity in Multiple Chronic Cough Preclinical Models - Jun 5th, 2025 11:00 pm
Addex to Present Positive GABAB PAM Chronic Cough Data at the 10th American Cough Conference - Jun 4th, 2025 11:00 pm
Addex Convenes Annual General Meeting 2025 - Jun 2nd, 2025 11:00 pm
Addex Partner Indivior Advances GABAB Positive Allosteric Modulator Program Successfully Through IND Enabling Studies - May 11th, 2025 11:00 pm
Addex Enters Option Agreement with Sinntaxis for an Exclusive License to Intellectual Property Covering the Use of mGlu5 Inhibitors in Brain Injury Recovery - Apr 29th, 2025 11:00 pm